Clinical effect of Lingnan Chen's flying needle in treating postmenopausal osteoporosis

注册号:

Registration number:

ITMCTR2000003117

最近更新日期:

Date of Last Refreshed on:

2020-03-15

注册时间:

Date of Registration:

2020-03-15

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

岭南陈氏飞针治疗绝经后骨质疏松症的临床效果

Public title:

Clinical effect of Lingnan Chen's flying needle in treating postmenopausal osteoporosis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺干预绝经后骨质疏松症的临床研究及机制探讨

Scientific title:

Clinical Study and Mechanism of Acupuncture on Postmenopausal Osteoporosis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000030848 ; ChiMCTR2000003117

申请注册联系人:

陈艳婷

研究负责人:

陈秀华

Applicant:

Chen Yanting

Study leader:

Chen Xiuhua

申请注册联系人电话:

Applicant telephone:

+86 13535328009

研究负责人电话:

Study leader's telephone:

+86 13710695743

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

13535328009@163.com

研究负责人电子邮件:

Study leader's E-mail:

867273961@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省广州市白云区机场路12号

研究负责人通讯地址:

广东省广州市越秀区大德路111号

Applicant address:

12 Airport Road, Baiyun District, Guangzhou, Guangdong, China

Study leader's address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong,China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学

Applicant's institution:

Guangzhou University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013/8/26 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州中医药大学第二附属医院

Primary sponsor:

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市越秀区大德路111号

Primary sponsor's address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州中医药大学第二附属医院

具体地址:

越秀区大德路111号

Institution
hospital:

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Address:

111 Dade Road, Yuexiu District

经费或物资来源:

自筹

Source(s) of funding:

Self-financing

研究疾病:

绝经后骨质疏松症

研究疾病代码:

Target disease:

Postmenopausal osteoporosis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

本研究拟通过开展临床研究,采用“岭南陈氏针法”进行临床干预,对比岭南陈氏针法与普通针刺治疗PMOP的临床疗效,为PMOP提供更安全有效的治疗手段。并基于GH/IGF-1轴探讨“岭南陈氏针法”治疗PMOP的作用机制,可为临床推广“岭南陈氏针法”治疗PMOP提供依据。

Objectives of Study:

This study intends to carry out clinical research and use "Lingnan Chen's Acupuncture" for clinical intervention, and compare the clinical efficacy of Lingnan Chen's Acupuncture with ordinary acupuncture in the treatment of PMOP, providing a safer and more effective treatment for PMOP. Based on the GH / IGF-1 axis, the mechanism of "Lingnan Chen's Acupuncture" in treating PMOP can be explored, which can provide a basis for clinical promotion of "Lingnan Chen's Acupuncture" in treating PMOP.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

① 年龄45~70岁,绝经时间超过1年者; ② 所有患者经双能X线吸收测量法(DXA)测定骨密度T值≤-2.5; ③ 同意进入本调查,并能较好的进行语言或书面交流。

Inclusion criteria

1. Aged 45 to 70 years, menopause time more than 1 year; 2. All patients with bone density T value <= -2.5 measured by dual energy X-ray absorptiometry (DXA); 3. Patients who agree to enter the survey and can communicate better in language or writing.

排除标准:

① 合并有必脑血管疾病,肝肾功能异常,造血系统严重疾病等等; ② 合并有恶性肿瘤及结核等疾病; ③ 排除其他因素所致的骨质疏松症患者,如甲状旁腺功能亢进、瘫痪等; ④ 严重的崎形、残疾等; ⑤ 患消化性溃疡、消化不良等病史者; ⑥ 近1年内接受过激素替代治疗(HRT)或入组前6个月内曾经服用过影响骨代谢的药物,如双磷酸盐、皮质醇、钙片、维生素D、氟化物、雌激素等。

Exclusion criteria:

1. Patients with essential cerebrovascular diseases, liver and kidney dysfunction, and severe hematopoietic system diseases etc.; 2. Patients with malignant tumor, tuberculosis and other diseases; 3. Patients with osteoporosis due to exclusion of other factors, such as hyperparathyroidism, Paralysis, etc.; 4. With serious ruggedness, disability, etc.; 5. Patients with a history of peptic ulcer, indigestion; 6. Have received hormone replacement therapy (HRT) in the past 1 year or have taken influence on bone metabolism within 6 months before enrollment Drugs, such as bisphosphate, cortisol, calcium tablets, vitamin D, fluoride, estrogen, etc.

研究实施时间:

Study execute time:

From 2020-04-10

To      2021-03-30

征募观察对象时间:

Recruiting time:

From 2020-04-10

To      2021-01-31

干预措施:

Interventions:

组别:

试验组

样本量:

50

Group:

experimental group

Sample size:

干预措施:

飞针

干预措施代码:

Intervention:

Flying acupuncture

Intervention code:

组别:

对照组

样本量:

50

Group:

control group

Sample size:

干预措施:

西药

干预措施代码:

Intervention:

Western medicine

Intervention code:

样本总量 Total sample size : 100

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州中医药大学第二附属医院

单位级别:

三级甲等

Institution/hospital:

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

骨密度

指标类型:

主要指标

Outcome:

Bone mineral density

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量评分

指标类型:

次要指标

Outcome:

Quality of life score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胰岛素样生长因子

指标类型:

主要指标

Outcome:

Insulin-like growth factor

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总 I 型胶原氨基端延长肽

指标类型:

次要指标

Outcome:

PINP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

性激素六项

指标类型:

次要指标

Outcome:

Sex hormone

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生长因子

指标类型:

主要指标

Outcome:

Growth factor

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 45
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

采取简单随机化方法分组。根据样本含量利用PEMS3.1统计软件包产生随机分配结果,制作随机卡片,加信封密封。合格病例进入试验时,依就诊顺序按信封上的序号拆开信封,依照随机卡片上的提示进行分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Take a simple randomization method to group. According to the sample content, a random distribution result is generated using the PEMS3.1 statistical software package, a random card is made, and an envelope is sealed. When qualified cases enter the test, the envelopes are opened according to the order of

盲法:

采用单盲法

Blinding:

Blind method for evaluators.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国知网

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://epub.cnki.net/kns/brief/result.aspx?dbprefix=scdb&UID=WEEvREcwSlJHSldTTEYzU3EycEhjYTRFQkxXQXArdE1FckpPN3JOWUhtVT0%3d%249A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!&autoLogin=1

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

一为病例记录表;二为电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

One is a case record form; the other is an electronic collection and management system.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above